Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 1 of 1 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/04/23
End: 05/31/27
Due: 05/31/28
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study Evaluating AB248 Alone or in Combination with Pembrolizumab in Adult Patients with Solid Tumors | NCT05653882 | Asher Biotherapeutics, Inc. | user2@example.com | None | 2023-01-04 | 2027-05-31 | 2028-05-31 | - | - | 2025-07-14 |